Investigational drug · Phase 2
HB0056
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Asthma, Idiopathic Pulmonary Fibrosis (IPF).
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "HB0056"
First trial start
2025
Aug 21, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HB0056", any sponsor or status.
Conditions studied
As listed on its trial records.
- Asthma
- Idiopathic Pulmonary Fibrosis (IPF)
Approved drugs for the same conditions: Asthma · Idiopathic pulmonary fibrosis · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "HB0056" as an intervention, largest first.
- A Study of HB0056 in Adult Participants With Moderate to Severe AsthmaPivotal-lookingRecruiting
Shanghai Huaota Biopharmaceutical Co., Ltd.Industry
NCT07899996 · 160 participants (planned) · Start Aug 21, 2025 · Primary completion Aug 1, 2027
Drug: Placebo; HB0056 · For: Asthma
Sites: Beijing, China · 2 sites in all
- A Phase 2 Study of HB0056 in Patients With Idiopathic Pulmonary FibrosisNot yet recruiting
Shanghai Huaota Biopharmaceutical Co., Ltd.Industry
NCT07909655 · 75 participants (planned) · Start Nov 2026 · Primary completion Jan 2028
Drug: HB0056; HB0056 and 1 more · For: Idiopathic Pulmonary Fibrosis (IPF)
Sites: Changsha, China; Shanghai, China
Shanghai Huaota Biopharmaceutical Co., Ltd.Industry
NCT06612970 · 46 participants · Start Nov 18, 2024 · Primary completion Jun 13, 2025
Drug: HB0056; Placebo · For: Healthy
Sites: Christchurch, New Zealand
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Asthma
- CM512Phase 39 trials
Keymed Biosciences Co.Ltd · Chronic Rhinosinusitis With Nasal Polyposis, Chronic Spontaneous Urticaria (CSU), Asthma
- LunsekimigSAR443765Phase 39 trials
Sanofi · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps
- GSK5784283Phase 38 trials
GSK · Pulmonary Disease, Chronic Obstructive, Asthma, Nasal Polyps
- PF-07275315tilrekimigPhase 38 trials
Pfizer · Atopic Dermatitis, Asthma, Moderate to Severe Chronic Obstructive Pulmonary Disease
- MG-K10Humanized Monoclonal AntibodyPhase 36 trials
Shanghai Mabgeek Biotech.Co.Ltd · Dermatitis, Atopic, Chronic Urticaria, Idiopathic, Atopic Dermatitis
- SHR-1905Phase 36 trials
Guangdong Hengrui Pharmaceutical Co., Ltd · Asthma, Chronic Rhinosinusitis With Nasal Polyps, Moderate-to-severe Atopic Dermatitis
- TozorakimabMEDI3506Phase 36 trials
AstraZeneca · Chronic Obstructive Pulmonary Disease (COPD), Asthma, Viral Lung Infection and Acute Respiratory Failure
- TQC2731Phase 35 trials
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.